Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002204 · ClinicalTrials.gov registry record · Phase 1
A Phase I, Observer-Blind, Placebo-Controlled Study of the Chiron Vaccine HIV p24/MF59 Administered to Healthy HIV-Seronegative Adults
A Phase 1 study, sponsored by Chiron Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT00002204 is a Phase 1 study that has completed, run by Chiron Corporation. The registered enrollment target is 40 participants.
The verdict
NCT00002204, a Phase 1 study, has completed, sponsored by Chiron Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
To evaluate the safety and tolerability of the Chiron vaccine human immunodeficiency virus (HIV) p24(25 or 50 micrograms)/MF59 in healthy HIV-1 seronegative adults. To evaluate the immunogenicity of the HIV p24(50 micrograms)/MF59 vaccine.
Interventions
- BIOLOGICAL HIV p24/MF59 Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002204
The ClinicalTrials.gov registry entry for NCT00002204 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Chiron Corporation, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which HIV p24/MF59 Vaccine is the first listed.
NCT00002204 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002204 about?
NCT00002204 is a clinical study titled "A Phase I, Observer-Blind, Placebo-Controlled Study of the Chiron Vaccine HIV p24/MF59 Administered to Healthy HIV-Seronegative Adults". To evaluate the safety and tolerability of the Chiron vaccine human immunodeficiency virus (HIV) p24(25 or 50 micrograms)/MF59 in healthy HIV-1 seronegative adults. To evaluate the immunogenicity of the HIV p24(50 micrograms)/MF59 vaccine.
What is the current status of trial NCT00002204?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants.
What interventions are being tested in trial NCT00002204?
The interventions under investigation include: HIV p24/MF59 Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00002204?
This trial is sponsored by Chiron Corporation, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.